【摘要】 目的观察吉非替尼(易瑞沙)治疗非小细胞肺癌(NSCLC)复发转移患者的疗效及其毒副反应。方法回顾性研究2007年2月～2010年2月我院各科治疗的非小细胞肺癌术后复发转移患者,分为A、B两组,A组以吉非替尼为二线治疗方案,B组以细胞毒药物作为二线方案而吉非替尼作为三线治疗方案,评价两组患者近期及远期的疗效。结果吉非替尼作为二线治疗方案,其疾病控制率(CR+PR+SD)为73%,有效率(CR+PR)为59%,6个月生存率为86%,1年生存率为45%;作为三线治疗,疾病控制率(CR+PR+SD)为56%,有效率(CR+PR)为38%,6个月生存率为76%,1年生存率为28%。结论对于转移复发非小细胞肺癌患者,尽早应用吉非替尼治疗可以使患者更大获益。更多还原

【Abstract】 Objective To observe therapeutic effect of gefitinib(Iressa)as second-line and third-line treatment in patients with non-small cell lung cancer(NSCLC)recurrence and metastasis.Methods Retrospective studies were made on NSCLC cases treated in our hospital from February 2007 to February 2010.51 patients were divided into A,B two groups.A group accepted the therapy of gefitinib as second-line treatment and B group accepted the therapy of cytotoxic drug as second-line treatment and gefitinib as third-line treatment.The short and long term effects were evaluated.Results In A group,disease control rate was 73%,effective rate was 59%,6-month survival rate was 86%,1-year survival rate was 45%.In B group,disease control rate was 56%,effective rate was 38%,6-month survival rate was 76%,1-year survival rate was 28%.Conclusion For non-small cell lung cancer with metastasis and recurrence in patients,earlier application of gefitinib therapy can benefit patients more.更多还原